ELTX
Elicio Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Bearish Engulfing
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ELTX
Elicio Therapeutics Inc
A biopharmaceutical company focused on novel small molecule therapeutics to address fibrotic diseases
451 D Street, 5th Floor, Boston, Massachusetts 02210
--
Elicio Therapeutics Inc was incorporated in Delaware on April 6, 1998. The company is a clinical-stage biotechnology company developing a novel immunotherapy pipeline for the treatment of cancer and disease. By combining expertise in immunology and immunotherapy, Elicio is designing investigational amphiphilic (AMP) immunotherapies designed to precisely target and fully engage lymph nodes. Elicio is designing node-targeting amplifiers, immunomodulators, adjuvants and vaccines for a range of aggressive cancers and infectious diseases.
Company Financials
EPS
ELTX has released its 2025 Q3 earnings. EPS was reported at -0.6, versus the expected -0.48, missing expectations. The chart below visualizes how ELTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
